Skip to Content

Hologic Inc HOLX Stock Quote

| Rating as of


Morningstar‘s Stock Analysis HOLX

Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Hologic Delivers Fiscal Fourth Quarter That Displays Solid Foundation for Longer-Term Growth

Debbie S. Wang Senior Equity Analyst

Analyst Note

| Debbie S. Wang |

Hologic posted fiscal fourth-quarter results that highlighted the firm’s ability to balance declines in COVID-19 tests with acceleration of its nonpandemic business. Following some minor adjustments to our 2023 assumptions, we’re leaving our fair value estimate unchanged. We give management much credit for its skillful navigation of both the COVID-19 opportunity in 2020-21 and the diminishing demand in 2022. Importantly, we think the firm’s investment of its COVID-19 windfall in expanding its test menu should put Hologic on a path toward faster diagnostic growth than seen before the pandemic. All of this underscores our confidence in Hologic’s narrow economic moat, and we expect to see the firm further leverage the switching costs that are associated with its diagnostic platforms.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics HOLX

Company Profile HOLX

Business Description

Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (64% of total sales, boosted by pandemic), breast health (21% of sales, suppressed by pandemic), surgical (12%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (75%), followed by Europe (16%), Asia (6%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.

Marlborough, MA, 01752
T +1 508 263-2900
Industry Medical Instruments & Supplies
Most Recent Earnings Sep 30, 2022
Fiscal Year End Sep 24, 2023
Employees 6,944